BioMed Research International / 2012 / Article / Tab 2

Research Article

Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects

Table 2

Association of PAI-1 4G/5G polymorphisms with type 2 diabetes mellitus in Malaysian subjects.

PAI-1 4G/5G polymorphismControl ( 𝑛 = 1 3 1 )Type 2 diabetes mellitusTotal type 2 diabetes mellitus ( 𝑛 = 3 0 3 )
Without MetS
( 𝑛 = 7 6 )
With MetS
( 𝑛 = 2 2 7 )

Risk allele frequency (4G)0.470.480.490.50
(4G/4G)/(4G/5G)/(5G/5G) (frequency)0.23/0.485/0.290.25/0.54/0.210.25/0.48/0.270.25/0.50/0.25
Recessive modelOdds ratio1.80.660.78
95% CI(0.77–4.2)(0.31–1.4)0.37–1.66
𝑃 value0.170.290.52
Dominant modelOdds ratio2.351.611.5
95% CI1.0–5.43(0.9–2.91)0.72–1.7
𝑃 value0.0450.110.28
Additive modelOdds ratio1.671.11.1
95% CI0.98–2.840.75–1.60.69–1.74
𝑃 value0.0580.630.69

In the additive model, genotype of homozygote for the nonrisk allele 5G/5G (0/0), heterozygote 4G/5G (1/0), and homozygote for the risk allele 4G/4G (1/1) were coded as 0, 1, and 2, respectively. The recessive model was defined as 4G/4G versus (4G/5G + 5G/5G), dominant model as (4G/4G + 4G/5G) versus 5G/5G, and additive model as 4G/4G versus 4G/5G versus 5G/5G. The results presented odds ratio, 95% CI, and 𝑃 value adjusted for age, gender, race, family history of diabetes, and BMI as covariates which evaluated by hierarchical logistic regression. MetS: metabolic syndrome.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.